Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)

Exclusion Criteria

• •1. Any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, sirolimus, or everolimus
• •2. An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment.
• •3. Acute ST-segment-elevation MI or cardiogenic shock
• •4. Terminal illness with life expectancy \<1 year
• •5. In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment). However, non-target vessel ISR is permitted.
• •6. Patients with EF\<30%.
• •7. Serum creatinine level ≥ 2.0mg/dL or dependence on dialysis.
• •8. Patients with left main stem stenosis (\>50% by visual estimate)